The tests led to a high concentration of chemical products in the infant syrup twice than the specified amount of the European pharmaceutical association. These chemical products may have side effects on infants’ liver and hormones on the long run.
The UAE Ministry of Health through the medical practices sector communicated with the GCC Regional Office for Glaxo Smith Kline to ensure that the serial number of the medicine in Taiwan is not contained in the UAE.
Furthermore, Dr. Ali Ziwar, Director of Medical Sector and Pharmaceutical Registration in Gulf Glaxo Smith Kline stated that the food and health authority in Taiwan tested the augmentin syrup, which proved the presence of a plastic product, which belongs to the DIDP Group that may have side effects on human bodies.
Meanwhile, Glaxo Smith Kline confirmed that it purchased the augmentin syrup “165 mg” in bottles from Saudi Arabia and carries a different serial number that the one mentioned in Taiwan which is originally imported from France.